Neuroimmunomodulation in medical oncology: Application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors

Paolo Lissoni, Fernando Brivio, Luca Fumagalli, Giusy Messina, Luigi Vigoré, Daniela Parolini, Massimo Colciago, Franco Rovelli

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background: Anticancer immunity is under psychoneuroendocrine regulation, mainly via the pineal gland and brain opioid system, which may stimulate and inhibit antitumor immunity respectively. Cancer-related immunosuppression does not depend only on functional damage of immune cells, but also on alterations of systems responsible for the neuroimmunomodulation, the most frequent of wich is a decline in blood levels of the pineal hormone melatonin (MLT). Patients and Methods: A study was performed to evaluate the influence of an exogenous administration of MLT alone or MLT plus subcutaneous (SC) low-dose interleukin-2 on tumor progression and survival time in patients with untreatable metastatic solid tumors. The study included 846 patients with metastatic solid tumor (non-small cell lung cancer or gastrointestinal tract tumors) randomized to receive the best supportive care only, supportive care plus MLT (20 mg/day, orally in the evening), or MLT plus SC low-dose IL-2 (3 MIU/day for 5 days/week, for 4 consecutive weeks). Results: The MLT alone was able to induce a significant increase of disease stabilization and survival time with respect to supportive care alone. The association of IL-2 with MLT provided a further improvement in the percentage of tumor regressions and of 3-year survival with respect to MLT alone. Conclusion: The administration of IL-2 and the pineal hormone MLT may induce control of neolplastic growth and a prolonged survival time in patients with metastatic solid tumors, for whom no other conventional anticancer therapy is available.

Original languageEnglish
Pages (from-to)1377-1381
Number of pages5
JournalAnticancer Research
Volume28
Issue number2 B
Publication statusPublished - Mar 2008

Fingerprint

Neuroimmunomodulation
Psychoneuroimmunology
Medical Oncology
Melatonin
Interleukin-2
Hormones
Neoplasms
Survival
Immunity
Gastrointestinal Neoplasms
Pineal Gland
Interleukin-3
Non-Small Cell Lung Carcinoma
Immunosuppression
Opioid Analgesics

Keywords

  • Cancer immunotherapy
  • IL-2
  • Melatonin
  • Neuroimmunomodulation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Neuroimmunomodulation in medical oncology : Application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors. / Lissoni, Paolo; Brivio, Fernando; Fumagalli, Luca; Messina, Giusy; Vigoré, Luigi; Parolini, Daniela; Colciago, Massimo; Rovelli, Franco.

In: Anticancer Research, Vol. 28, No. 2 B, 03.2008, p. 1377-1381.

Research output: Contribution to journalArticle

Lissoni, Paolo ; Brivio, Fernando ; Fumagalli, Luca ; Messina, Giusy ; Vigoré, Luigi ; Parolini, Daniela ; Colciago, Massimo ; Rovelli, Franco. / Neuroimmunomodulation in medical oncology : Application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors. In: Anticancer Research. 2008 ; Vol. 28, No. 2 B. pp. 1377-1381.
@article{f7d366d7d3a54e9fa7a9178e435bb5e6,
title = "Neuroimmunomodulation in medical oncology: Application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors",
abstract = "Background: Anticancer immunity is under psychoneuroendocrine regulation, mainly via the pineal gland and brain opioid system, which may stimulate and inhibit antitumor immunity respectively. Cancer-related immunosuppression does not depend only on functional damage of immune cells, but also on alterations of systems responsible for the neuroimmunomodulation, the most frequent of wich is a decline in blood levels of the pineal hormone melatonin (MLT). Patients and Methods: A study was performed to evaluate the influence of an exogenous administration of MLT alone or MLT plus subcutaneous (SC) low-dose interleukin-2 on tumor progression and survival time in patients with untreatable metastatic solid tumors. The study included 846 patients with metastatic solid tumor (non-small cell lung cancer or gastrointestinal tract tumors) randomized to receive the best supportive care only, supportive care plus MLT (20 mg/day, orally in the evening), or MLT plus SC low-dose IL-2 (3 MIU/day for 5 days/week, for 4 consecutive weeks). Results: The MLT alone was able to induce a significant increase of disease stabilization and survival time with respect to supportive care alone. The association of IL-2 with MLT provided a further improvement in the percentage of tumor regressions and of 3-year survival with respect to MLT alone. Conclusion: The administration of IL-2 and the pineal hormone MLT may induce control of neolplastic growth and a prolonged survival time in patients with metastatic solid tumors, for whom no other conventional anticancer therapy is available.",
keywords = "Cancer immunotherapy, IL-2, Melatonin, Neuroimmunomodulation",
author = "Paolo Lissoni and Fernando Brivio and Luca Fumagalli and Giusy Messina and Luigi Vigor{\'e} and Daniela Parolini and Massimo Colciago and Franco Rovelli",
year = "2008",
month = "3",
language = "English",
volume = "28",
pages = "1377--1381",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 B",

}

TY - JOUR

T1 - Neuroimmunomodulation in medical oncology

T2 - Application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors

AU - Lissoni, Paolo

AU - Brivio, Fernando

AU - Fumagalli, Luca

AU - Messina, Giusy

AU - Vigoré, Luigi

AU - Parolini, Daniela

AU - Colciago, Massimo

AU - Rovelli, Franco

PY - 2008/3

Y1 - 2008/3

N2 - Background: Anticancer immunity is under psychoneuroendocrine regulation, mainly via the pineal gland and brain opioid system, which may stimulate and inhibit antitumor immunity respectively. Cancer-related immunosuppression does not depend only on functional damage of immune cells, but also on alterations of systems responsible for the neuroimmunomodulation, the most frequent of wich is a decline in blood levels of the pineal hormone melatonin (MLT). Patients and Methods: A study was performed to evaluate the influence of an exogenous administration of MLT alone or MLT plus subcutaneous (SC) low-dose interleukin-2 on tumor progression and survival time in patients with untreatable metastatic solid tumors. The study included 846 patients with metastatic solid tumor (non-small cell lung cancer or gastrointestinal tract tumors) randomized to receive the best supportive care only, supportive care plus MLT (20 mg/day, orally in the evening), or MLT plus SC low-dose IL-2 (3 MIU/day for 5 days/week, for 4 consecutive weeks). Results: The MLT alone was able to induce a significant increase of disease stabilization and survival time with respect to supportive care alone. The association of IL-2 with MLT provided a further improvement in the percentage of tumor regressions and of 3-year survival with respect to MLT alone. Conclusion: The administration of IL-2 and the pineal hormone MLT may induce control of neolplastic growth and a prolonged survival time in patients with metastatic solid tumors, for whom no other conventional anticancer therapy is available.

AB - Background: Anticancer immunity is under psychoneuroendocrine regulation, mainly via the pineal gland and brain opioid system, which may stimulate and inhibit antitumor immunity respectively. Cancer-related immunosuppression does not depend only on functional damage of immune cells, but also on alterations of systems responsible for the neuroimmunomodulation, the most frequent of wich is a decline in blood levels of the pineal hormone melatonin (MLT). Patients and Methods: A study was performed to evaluate the influence of an exogenous administration of MLT alone or MLT plus subcutaneous (SC) low-dose interleukin-2 on tumor progression and survival time in patients with untreatable metastatic solid tumors. The study included 846 patients with metastatic solid tumor (non-small cell lung cancer or gastrointestinal tract tumors) randomized to receive the best supportive care only, supportive care plus MLT (20 mg/day, orally in the evening), or MLT plus SC low-dose IL-2 (3 MIU/day for 5 days/week, for 4 consecutive weeks). Results: The MLT alone was able to induce a significant increase of disease stabilization and survival time with respect to supportive care alone. The association of IL-2 with MLT provided a further improvement in the percentage of tumor regressions and of 3-year survival with respect to MLT alone. Conclusion: The administration of IL-2 and the pineal hormone MLT may induce control of neolplastic growth and a prolonged survival time in patients with metastatic solid tumors, for whom no other conventional anticancer therapy is available.

KW - Cancer immunotherapy

KW - IL-2

KW - Melatonin

KW - Neuroimmunomodulation

UR - http://www.scopus.com/inward/record.url?scp=42549091038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42549091038&partnerID=8YFLogxK

M3 - Article

C2 - 18505083

AN - SCOPUS:42549091038

VL - 28

SP - 1377

EP - 1381

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 B

ER -